Safety and immunogenicity of live intranasal pertussis vaccine GamLVP in the experimental infant hamadryas baboon model

Safety and immunogenicity of live intranasal pertussis vaccine GamLVP in the experimental infant hamadryas baboon model

Introduction. The Gamaleya National Center of Epidemiology and Microbiology has developed a live intranasal pertussis vaccine, GamLVP, for protection against whooping cough. It is indicated for vaccination of infants and revaccination of adults of all age groups. Preclinical studies on suckling mice...

Full description

Bibliographic Details
Main Authors: A. A. Djidaryan, A. Z. Matua, A. Yu. Medkova, E. G. Semin, L. N. Sinyashina, I. N. Dyakov, I. N. Chernyshova, D. T. Kubrava, A. A. Amichba, I. G. Kondzariya, Z. Ya. Mikvabiya, G. I. Karataev
Format: Article
Language:Russian
Published: Central Research Institute for Epidemiology 2022-05-01
Series:Журнал микробиологии, эпидемиологии и иммунобиологии
Subjects:
pertussis
live pertussis vaccine
intranasal administration
hamadryas baboons
papio hamadryas
experimental model
immunogenicity
safety
Online Access:https://microbiol.elpub.ru/jour/article/view/1218

Internet

https://microbiol.elpub.ru/jour/article/view/1218

Similar Items